Abstract
Cardiovascular diseases are a very important cause of morbidity and mortality in patients with prostate cancer. Androgen deprivation and androgen receptor signaling therapy (ARTA) increase the risk of cardiovascular complications.
Data from randomized trials and clinical practice indicate that when ARTA is used after docetaxel chemotherapy, the cardiovascular risk is even higher than when these drugs are used in the pre-treatment indication. There is an association between prostate cancer and sinus fibrillation, which is an independent predictor of mortality in these patients.
In particular, the induced hypoandrogenic state and hypokalemia associated with hormonal treatment contribute to the prolongation of the QT interval in patients with prostate cancer.